# Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

> **NCT01817582** · PHASE2 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 102 (actual)

## Conditions studied

- Keratoconjunctivitis Sicca

## Interventions

- **DRUG:** Lotemax
- **DRUG:** Restasis
- **DRUG:** Soothe® Lubricant Eye Drops

## Key facts

- **NCT ID:** NCT01817582
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-17
- **Primary completion:** 2014-01-10
- **Final completion:** 2014-01-10
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2019-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01817582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01817582, "Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01817582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*